XBiotech Announces Participation in European Colorectal Cancer Roundtable

Event, titled “Colorectal Cancer in Europe: A Call to Action,” to Feature XBiotech Medical Director Dr. Michael Stecher in Multidisciplinary Panel in a High Level Forum

XBiotech’s Medical Director Michael Stecher, M.D., will participate in a multidisciplinary meeting titled ‘Colorectal Cancer in Europe: A Call to Action,’ being held May 27, 2015 in Brussels, Belgium. Following the round-table meeting, a report will be published and disseminated across Europe in September to all relevant stakeholders including Ministries of Health, health administrations, health associations and patient advocacy groups. The purpose of the meeting and subsequent report is to identify what actions need to be taken in order to reduce colorectal cancer (CRC) morbidity and mortality rates in Europe over the next 5 years and to encourage an examination of current policies and practices relating to CRC screening, management and care.

Colorectal cancer is currently the second leading cause of cancer death in Europe; the incidence of colorectal cancer is expected to rise 12% by 2020. However, a number of European countries still do not have a national CRC screening program. This meeting will bring together Members of the European Parliament, representatives of Ministries of Health from EU Member States, a representative of the European Commission, patient advocacy groups and leading expert physicians, to openly discuss a variety of key issues and raise greater awareness of colorectal cancer.

Dr. Stecher commented, "Increased research and innovation in the public and private sectors are essential to reducing morbidity and mortality rates in patients with advanced colorectal cancer. As we continue Phase 3 development for Xilonix™ in colorectal cancer and advance toward a possible approval, we believe that it is important to participate in multidisciplinary efforts to improve colorectal cancer screening and care."

XBiotech is currently studying its lead product, Xilonix™, in Phase 3 trials in the United States and Europe for the treatment of symptomatic colorectal cancer in patients refractory to standard therapy. Xilonix™ is a monoclonal antibody designed to neutralize biological activity of interleukin-1 alpha (IL-1a), a pro-inflammatory protein produced by leukocytes and other cells. In a previous study at MD Anderson, Xilonix™ therapy appeared to not only have anti-tumor effects and prolong survival, but also seemed to improve symptoms of muscle loss, fatigue, appetite loss, and pain in patients with advanced cancer.